Announcement on Shareholding Reduction Plan of Senior Executive
Filed with SSE · · 6 pages · Chinese
Summary by 6ix AI
Dizal (Jiangsu) Pharmaceutical Co. Ltd. has announced a shareholding reduction plan for several senior executives due to personal funding needs. The executives involved include the Chief Financial Officer and several Vice Presidents, each planning to reduce their holdings through a centralized bidding process. The company assures that this reduction will not affect its governance or ongoing operations.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Dizal (Jiangsu) Pharmaceutical Co. Ltd. on 6ix
Earlier from Dizal (Jiangsu) Pharmaceutical
- Announcement on Voluntary Disclosure of Publication of Research Results on Birelentinib for the Treatment of Diffuse Large B-Cell Lymphoma in "Blood Cancer Journal"
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the Innovative Drug Industry
- Announcement on Shareholding Reduction Plan of Directors and Senior Management
- Announcement on Voluntary Disclosure of the Acceptance by the U.S. FDA of the Supplemental New Drug Application for Sunvozertinib as a Monotherapy for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
- Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
Later from Dizal (Jiangsu) Pharmaceutical
- Announcement on Use of Temporarily Idle Self-owned Funds for Entrusted Wealth Management
- (688192)"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Receipt of a USD 600 Million Upfront Payment from AstraZeneca for the Global Licensing of ZEGFROVY
- (688192)"DIZAL PHARMACEUTICAL CO., LTD."Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares and Its Persons Acting in Concert Reaching an Integer Multiple of 5% Threshold and Disclosure of Simplified Report on Change in Equity Interests
- (688192)"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Convening the Q3 2026 Performance Briefing
- (688192)"DIZAL PHARMACEUTICAL CO., LTD."Report for Q3 2026
Follow Dizal (Jiangsu) Pharmaceutical into a list and get an email when it puts out news.
Follow Dizal (Jiangsu) Pharmaceutical